AVITA Medical, Inc. (RCEL)
NASDAQ: RCEL · Real-Time Price · USD
13.05
+0.09 (0.69%)
At close: Nov 20, 2024, 4:00 PM
12.96
-0.09 (-0.69%)
After-hours: Nov 20, 2024, 7:02 PM EST
AVITA Medical Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for AVITA Medical stock have an average target of 16.5, with a low estimate of 12 and a high estimate of 21. The average target predicts an increase of 26.44% from the current stock price of 13.05.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for AVITA Medical stock from 3 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Hold Reiterates $9 → $12 | Hold | Reiterates | $9 → $12 | -8.05% | Nov 8, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $21 | Buy | Reiterates | $21 | +60.92% | Aug 9, 2024 |
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $21 → $9 | Buy → Hold | Downgrades | $21 → $9 | -31.03% | May 14, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $22 → $21 | Buy | Maintains | $22 → $21 | +60.92% | May 14, 2024 |
| BTIG | BTIG | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Apr 11, 2024 |
Financial Forecast
Revenue This Year
67.56M
from 50.14M
Increased by 34.73%
Revenue Next Year
104.45M
from 67.56M
Increased by 54.61%
EPS This Year
-1.84
from -1.40
EPS Next Year
-0.90
from -1.84
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 72.7M | 115.6M | 151.7M | |
| Avg | 67.6M | 104.5M | 132.5M | |
| Low | 50.6M | 94.6M | 113.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | 44.9% | 71.1% | 45.3% | |
| Avg | 34.7% | 54.6% | 26.8% | |
| Low | 0.8% | 40.0% | 8.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -0.37 | -0.18 | 0.09 | |
| Avg | -1.84 | -0.90 | -0.21 | |
| Low | -2.48 | -1.75 | -0.86 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.